Strategy

R&D

Making accessibility strategy part of your rare disease tria...

Over the past several years, diversity, equity, and inclusion (DEI) has become a central subject of conversation in clinical trials.

R&D

New strategies to manage clinical trial risk

It is essential for healthcare and pharmaceutical companies to be aware of both critical and non-critical risks when conducting quality clinical trials.

News

Naoki Okamura named as next CEO of Astellas

Kenji Yasukawa is stepping down as chief executive of Japanese pharma group Astellas, to be succeeded by Naoki Okamura – currently chief strategy officer – on 1st April.

Digital

The importance of AI literacy in life sciences

The promise and value of artificial intelligence (AI) in life sciences are somewhat obscured by the over-generalisation of this technology.

Sales & Marketing

Another inside peek into pharma marketing at PM Society lear...

The PM Society’s ‘Is Pharma Marketing built on Straw, Sticks, or Bricks?’ interactive information afternoon, held at The Royal Society of Medicine in London late last year, set out to bring

M&A

How to get acquisition ready – a seller’s guide to merger an...

This year, the predicted flurry of merger and acquisition (M&A) activity might not have materialised. However, as we near the end of the year, there were some big moves.